Distinct association of serum FGF21 or adiponectin levels with clinical parameters in patients with type 2 diabetes

被引:36
作者
Eto, Kazuhiro [1 ,2 ]
Tumenbayar, Bayasgalan [2 ]
Nagashima, Shu-ichi [2 ]
Tazoe, Fumiko [2 ]
Miyamoto, Michiaki [2 ]
Takahashi, Manabu [2 ]
Ando, Akihiko [2 ]
Okada, Kenta [2 ]
Yagyu, Hiroaki [2 ]
Ishibashi, Shun [2 ]
机构
[1] Teikyo Univ, Sch Med, Dept Internal Med, Itabashi Ku, Tokyo 1738605, Japan
[2] Jichi Med Univ, Dept Med, Div Endocrinol & Metab, Shimotsuke, Tochigi 3290498, Japan
关键词
FGF21; Adiponectin; Type; 2; diabetes; ACTIVATED-RECEPTOR-GAMMA; PPAR-ALPHA; FIBROBLAST-GROWTH-FACTOR-21; MELLITUS; FGF-21; IDENTIFICATION; METABOLISM; REGULATOR; DISEASES; KLOTHO;
D O I
10.1016/j.diabres.2010.03.019
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Fibroblast growth factor 21 (FGF21) has been identified as a novel metabolic regulator. This cross-sectional study was performed to clarify how serum FGF21 levels were associated with clinical parameters in Japanese subjects with type 2 diabetes (n = 139). Anthropometric and blood biochemical parameters, uses of drugs for diabetes, hypertension and dyslipidemia were examined regarding associations with fasting serum FGF21 concentrations. FGF21 levels were 6-times higher in those subjects taking fibrates. However, a use of thiazolidinediones did not affect serum FGF21 levels while it induced higher serum adiponectin levels. In univariate analyses, FGF21 levels showed associations with a use of fibrates, triglyceride levels, creatinine levels, waist circumference, and BMI. Multiple regression analyses adjusted for age, gender and BMI showed that a use of fibrates, triglyceride levels and creatinine levels were strong contributors to serum FGF21 levels. In contrast, a use of thiazolidinediones, HDL-cholesterol levels and fasting insulin levels were strong contributors to serum adiponectin levels. This study revealed that serum FGF21 levels were biochemical indicators correlating to a set of essential metabolic parameters, which was distinct from that correlating to serum adiponectin levels in subjects with type 2 diabetes. (C) 2010 Elsevier Ireland Ltd. All rights reserved.
引用
收藏
页码:52 / 57
页数:6
相关论文
共 25 条
[1]  
Badman MK, 2007, CELL METAB, V5, P426, DOI 10.1016/j.cmet.2007.05.002
[2]   Circulating FGF-21 levels in normal subjects and in newly diagnose patients with type 2 diabetes Mellitus [J].
Chen, W. -W. ;
Li, L. ;
Yang, G. -Y. ;
Li, K. ;
Qi, X. -Y. ;
Zhu, W. ;
Tang, Y. ;
Liu, H. ;
Boden, G. .
EXPERIMENTAL AND CLINICAL ENDOCRINOLOGY & DIABETES, 2008, 116 (01) :65-68
[3]  
Fruchart JC, 2008, AM J CARDIOL, V102, p1K, DOI [10.1016/j.amjcard.2008.10.002, 10.1016/S0002-9149(08)01833-X]
[4]  
HOJMAN P, 2009, FIBROBLAST GROWTH FA
[5]   The fasting polypeptide FGF21 can enter brain from blood [J].
Hsuchou, Hung ;
Pan, Weihong ;
Kastin, Abba J. .
PEPTIDES, 2007, 28 (12) :2382-2386
[6]   Fibroblast growth factor 15 functions as an enterohepatic signal to regulate bile acid homeostasis [J].
Inagaki, T ;
Choi, M ;
Moschetta, A ;
Peng, L ;
Cummins, CL ;
McDonald, JG ;
Luo, G ;
Jones, SA ;
Goodwin, B ;
Richardson, JA ;
Gerard, RD ;
Repa, JJ ;
Mangelsdorf, DJ ;
Kliewer, SA .
CELL METABOLISM, 2005, 2 (04) :217-225
[7]   Endocrine regulation of the fasting response by PPARα-mediated induction of fibroblast growth factor 21 [J].
Inagaki, Takeshi ;
Dutchak, Paul ;
Zhao, Guixiang ;
Ding, Xunshan ;
Gautron, Laurent ;
Parameswara, Vinay ;
Li, Yong ;
Goetz, Regina ;
Mohammadi, Moosa ;
Esser, Victoria ;
Elmquist, Joel K. ;
Gerard, Robert D. ;
Burgess, Shawn C. ;
Hammer, Robert E. ;
Mangelsdorf, David J. ;
Kliewer, Steven A. .
CELL METABOLISM, 2007, 5 (06) :415-425
[8]   FGF21 is an Akt-regulated myokine [J].
Izumiya, Yasuhiro ;
Bina, Holly A. ;
Ouchi, Noriyuki ;
Akasaki, Yuichi ;
Kharitonenkov, Alexei ;
Walsh, Kenneth .
FEBS LETTERS, 2008, 582 (27) :3805-3810
[9]   Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study):: randomised controlled trial [J].
Keech, A ;
Simes, RJ ;
Barter, P ;
Best, J ;
Scott, R ;
Taskinen, MR ;
Forder, P ;
Pillai, A ;
Davis, T ;
Glasziou, P ;
Drury, P ;
Kesäniemi, YA ;
Sullivan, D ;
Hunt, D ;
Colman, P ;
d'Emden, M ;
Whiting, M ;
Ehnholm, C ;
Laakso, M .
LANCET, 2005, 366 (9500) :1849-1861
[10]   FGF-21 as a novel metabolic regulator [J].
Kharitonenkov, A ;
Shiyanova, TL ;
Koester, A ;
Ford, AM ;
Micanovic, R ;
Galbreath, EJ ;
Sandusky, GE ;
Hammond, LJ ;
Moyers, JS ;
Owens, RA ;
Gromada, J ;
Brozinick, JT ;
Hawkins, ED ;
Wroblewski, VJ ;
Li, DS ;
Mehrbod, F ;
Jaskunas, SR ;
Shanafelt, AB .
JOURNAL OF CLINICAL INVESTIGATION, 2005, 115 (06) :1627-1635